Researchers at the University of Cincinnati and Johns Hopkins Medicine have developed a nanofiber implant that delivers three anti-cancer drugs directly to brain tumors, doubling survival rates in mice with glioblastoma, the most aggressive form of brain cancer.
The implant uses nanofibers, tiny thread-like structures, as a delivery system for drugs that work together to attack tumors from multiple angles. The combination proved more effective than any single drug alone, addressing a persistent challenge in glioblastoma treatment: the disease's resistance to conventional therapies.
The nanofiber design offers a dual-action approach. Some drugs release immediately after implantation to kill existing cancer cells, while others release gradually over time to prevent tumor regrowth. This sustained delivery mechanism keeps therapeutic concentrations at the tumor site without the systemic side effects that often accompany intravenous chemotherapy.
In mouse models, the tri-drug nanofiber implant doubled survival compared to untreated controls. The researchers tested various drug combinations to identify which worked synergistically, then embedded the optimal cocktail into the nanofibers before surgical placement at the tumor site.
Glioblastoma remains one of oncology's hardest challenges. Median survival for patients diagnosed with the disease hovers around 15 months despite aggressive treatment with surgery, radiation, and chemotherapy. The blood-brain barrier, which protects the brain from harmful substances, also blocks many drugs from reaching tumors, limiting therapeutic options.
The nanofiber approach circumvents this problem by delivering drugs directly to the tumor. Because the implant sits at the tumor site rather than circulating throughout the body, doctors can use higher concentrations of drugs with minimal toxicity to healthy brain tissue.
The team has not yet disclosed which specific drugs they embedded in the nanofibers, though the work builds on prior research